Last reviewed · How we verify
MV-140
At a glance
| Generic name | MV-140 |
|---|---|
| Sponsor | Unidade Local de Saúde Santa Maria |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- MV-140 Efficacy in Recurrent Urinary Tract Infections in a Cohort of Portuguese Adult Patients
- Expanded Access Program Using Uromune for Patients With Recurrent Urinary Tract Infections (rUTI)
- Evaluation of the Efficacy and Safety of MV140 (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MV-140 CI brief — competitive landscape report
- MV-140 updates RSS · CI watch RSS
- Unidade Local de Saúde Santa Maria portfolio CI